1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Heart Transplant Rejection - Drugs In Development, 2022, provides an overview of the Heart Transplant Rejection (Immunology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Heart transplantation is the therapy used in various heart diseases. Heart transplant replaces an injured or diseased heart with a healthy one. Risk factors associated with transplantation are bleeding, infection, clots, and cardiovascular disorders. Following a transplant, the immune system may consider the transplanted heart as foreign and may work against it. Patients may hence develop complications and eventually reject the new organ. Immunosuppressive drugs are administered simultaneously which prevent the body from either identifying or attacking the foreign organ via various immune responses thus blocking organ rejection and facilitating a successful transplant.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Heart Transplant Rejection - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Heart Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Heart Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Heart Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 4 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.
Heart Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Heart Transplant Rejection (Immunology).
- The pipeline guide reviews pipeline therapeutics for Heart Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Heart Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Heart Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Heart Transplant Rejection (Immunology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Heart Transplant Rejection (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Heart Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Heart Transplant Rejection - Overview
- Heart Transplant Rejection - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Heart Transplant Rejection - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Heart Transplant Rejection - Companies Involved in Therapeutics Development
- Astellas Pharma Inc
- Bristol-Myers Squibb Co
- Kiniksa Pharmaceuticals Ltd
- Nekonal Sarl
- Tonix Pharmaceuticals Holding Corp
- Heart Transplant Rejection - Drug Profiles
- AS-2521780 - Drug Profile
- Product Description
- Mechanism Of Action
- AS-2553627 - Drug Profile
- Product Description
- Mechanism Of Action
- Autologous thyTreg - Drug Profile
- Product Description
- Mechanism Of Action
- belatacept - Drug Profile
- Product Description
- Mechanism Of Action
- KPL-404 - Drug Profile
- Product Description
- Mechanism Of Action
- Monoclonal Antibody to Inhibit TIRC-7 for Cardiac and Kidney Transplantation - Drug Profile
- Product Description
- Mechanism Of Action
- TNX-1500 - Drug Profile
- Product Description
- Mechanism Of Action
- tofacitinib - Drug Profile
- Product Description
- Mechanism Of Action
- Heart Transplant Rejection - Dormant Projects
- Heart Transplant Rejection - Product Development Milestones
- Featured News & Press Releases
- May 31, 2022: Tonix Pharmaceuticals announces two oral presentations involving TNX-1500 (Fc-modified anti-CD40L mAb) on prevention of rejection in kidney and heart allograft transplantation at the 2022 American Transplant Congress
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- Number of Products under Development for Heart Transplant Rejection, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Heart Transplant Rejection - Pipeline by Astellas Pharma Inc, 2022
- Heart Transplant Rejection - Pipeline by Bristol-Myers Squibb Co, 2022
- Heart Transplant Rejection - Pipeline by Kiniksa Pharmaceuticals Ltd, 2022
- Heart Transplant Rejection - Pipeline by Nekonal Sarl, 2022
- Heart Transplant Rejection - Pipeline by Tonix Pharmaceuticals Holding Corp, 2022
- Heart Transplant Rejection - Dormant Projects, 2022
- Number of Products under Development for Heart Transplant Rejection, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Targets, 2022
- Number of Products by Stage and Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Astellas Pharma Inc
- Bristol-Myers Squibb Co
- Kiniksa Pharmaceuticals Ltd
- Nekonal Sarl
- Tonix Pharmaceuticals Holding Corp
